Related Experiment Video
Updated: Jun 4, 2025
06:37
Temporomandibular Joint Pain Measurement by Bite Force and Von Frey Filament Assays in Mice
Published on: September 13, 2024
864
Association Between Temporomandibular Disorders and Irritable Bowel Syndrome: A Scoping Review
Klara Saczuk1, Sylwia Roszuk2, Malgorzata Wirkijowska2
1Department of General Dentistry, Medical University of Lodz, 251 Pomorska St., 92-213 Lodz, Poland.
Journal of Clinical Medicine
|December 17, 2024
Summary
Temporomandibular disorders (TMDs) and irritable bowel syndrome (IBS) are linked, with each condition worsening the other. Combined treatments may improve patient quality of life, but more research is needed.
Area of Science:
- Medical Science
- Gastroenterology
- Dentistry
Background:
- Temporomandibular disorders (TMDs) involve the temporomandibular joint and masticatory muscles, causing orofacial pain and restricted jaw movement.
- Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits.
- Existing research suggests a correlation between TMD and IBS, impacting quality of life and potentially leading to widespread pain.
Purpose of the Study:
- To examine the correlation between TMD and IBS.
- To investigate the pathology, frequency, and severity of both conditions.
- To explore the influence of nervous and endocrine systems on TMD and IBS.
Main Methods:
- A scoping review was conducted.
- Studies were identified using PubMed, SCOPUS, Web of Science, and Google Scholar.
- Fifty-eight clinical papers met the eligibility criteria for inclusion.
Main Results:
- TMD and IBS significantly enhance the development of one another.
- Mutual comorbidities and high comorbidity rates were observed in patients with both conditions.
- Both conditions were found to modify central nervous system processing.
Conclusions:
- A bidirectional relationship exists between TMD and IBS.
- Integrated dental and gastroenterological treatments can improve patient quality of life.
- Further research is recommended for a holistic treatment approach.
More Related Videos
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
244
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
244
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
139
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
139
01:17Chronic Bowel Disorders: Introduction
386
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
386
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
166
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
166
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
135
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
135
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147